Topic summary

AOD-9604 and the fragment hypothesis, revisited — does this still hold?

Compounds › Other compounds research use only needs a source mislabelling Solved

This is a generated summary. It shows the 5 most-liked posts from a topic of 12, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

n.laurentTL2 Moderator8 Nov 2025#1

The question in the title: AOD-9604 and the fragment hypothesis, revisited — does this still hold? I will give what I have already checked below so nobody repeats it.

Comparing FLOW (N Engl J Med, 2024) with SURMOUNT-OSA (N Engl J Med, 2024) and finding the comparison harder than it looks.

Different populations, different durations, different endpoints defined slightly differently, and in one case a different estimand. People compare the headline percentages anyway, including me until recently.

Is there a defensible way to put these side by side, or is the honest answer that there is not and we should stop?

50 likes 9mo

k.kuuselaTL2 Moderator18 Dec 2025#2

Picking up the opening post: that is the part I would want checked first.

AOD-9604 is a fragment of human growth hormone and has been discussed as a potential weight-loss agent based on theoretical mechanism. The fragment hypothesis — that the fragment retains a specific property of the intact hormone — is not settled for this compound.

13 likes 7mo

IsaksenTL3Regular7 Mar 2026#5

Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption or treatment. The label does not tell you whether the molecule is safe, efficacious, or what its effects are.

20 likes 5mo

isotonic_driftTL1Member Solution31 May 2026#9

Sequence verification: for an obscure compound, a report of the amino acid sequence or a mass-spectrometry result confirming the mass is the only verification that actually matters. A supplier's certificate stating the name is not verification.

14 likes 2mo

i.amankwahTL2 Moderator27 Jul 2026#12

Compounds this community declines to help with, and why: there are specifics in the guidelines and they are not arbitrary. They exist because of failure modes that have happened in real people, not because of prudishness.

11 likes 19h

Read the full topic (12 posts)

This topic was referenced in

Revisiting: Melanocortin agonists: mechanism and the documented adverse profileCompounds › Other compounds · 141 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
Coming back to: Reading a supplier's product description as a marketing document Compounds › Other compounds needs a source custom synthesis research use only mislabelling Reading a supplier's product description as a marketing document Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in…	+35	39	688	5mo
Naming conventions for research peptides and the confusion they cause — one year on Compounds › Other compounds research use only mislabelling needs a source Naming conventions for research peptides and the confusion they cause — one year on — setting out what I have, and where I think it stops being reliable. I have seen SURMOUNT-2 ( Lancet , 2023) cited in…	+1	5	181	2y
Why catalogue breadth is not evidence of anything — what changed since Compounds › Other compounds custom synthesis mislabelling needs a source research use only Asking directly, because I could not find a straight answer: Why catalogue breadth is not evidence of anything — what changed since Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…	+62	66	26k	10mo
Reading a supplier's product description as a marketing document Compounds › Other compounds custom synthesis needs a source mislabelling On the subject in the title: Reading a supplier's product description as a marketing document Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim I…	+86	97	62k	8mo
Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Compounds › Other compounds custom synthesis mislabelling research use only Solved Posting this under the heading it deserves: Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Everything below is what sits behind that. Comparing SURMOUNT-4 ( JAMA , 2024) with…	+119	141	22k	20mo

Related topics — sharing the tags research use only, needs a source, mislabelling

Topic	Participants	Replies	Views	Activity
Insulin combinations and hypoglycaemia risk Practice › Interactions metformin needs a source hypoglycaemia insulin Closed On the subject in the title: Insulin combinations and hypoglycaemia risk Working notes rather than a conclusion. Practical question with the units stated, because I have seen how quickly these go wrong…	+18	22	7.8k	13mo
Revisiting: Oral versus injected administration claims for BPC-157 Compounds › Repair & healing peptides observational data needs a source TB-500 BPC-157 Solved On the subject in the title: Revisiting: Oral versus injected administration claims for BPC-157 Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I…	+23	27	7.7k	15mo
Research-use-only labelling: what it means and what it does not Sourcing › Regulatory compounding research use only EMA FDA Posting this under the heading it deserves: Research-use-only labelling: what it means and what it does not Everything below is what sits behind that. I would like to talk about documentation quality as a…	+100	110	37k	5mo
[2026 update] Conference abstracts as evidence: the weakest common citation Evidence › Preprints needs a source effect size preprint risk of bias Closed Conference abstracts as evidence: the weakest common citation — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURMOUNT-4 ( JAMA , 2024) and finding…		2	48k	7mo
Citing a preprint in a maintained document: our rule and its reasoning Evidence › Preprints risk of bias effect size needs a source preprint Pinned On the subject in the title: Citing a preprint in a maintained document: our rule and its reasoning Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a…		2	467	4mo